Please enable JS

5 reasons biosimilars must have distinguishable names

7/ 27

ARTICLE DETAILS

AUTHOR: 50SN Staff

DATE: Jul 27, 2015

TAGS:

SHARE ON: Twitter - Facebook - LinkedIn

5 reasons biosimilars must have distinguishable names

If you ask patients with severe chronic diseases, such as those with rheumatoid arthritis, cancer, or multiple sclerosis, what they believe is the most important factor in achieving a positive outcome for their condition or disease, the vast majority will say it’s the relationship they have with their physician and treatment team. Patients trust their physicians to recommend treatments and prescribe medications with a thorough understanding of how that regimen might affect them, while being vigilant to monitor for adverse reactions.

Graphic for 50state post

Click Here to read more